Nathalie Broutet.

Gibrilla F. Deen, M.D ., Barbara Knust, D.V.M., Nathalie Broutet, M.D., Ph.D., Foday R. Sesay, M.D., Pierre Formenty, D.V.M., Christine Ross, M.D., Anna E. Thorson, M.D., Ph.D., Thomas A. Massaquoi, M.D., Jaclyn E. Marrinan, M.Sc., Elizabeth Ervin, M.P.H., Amara Jambai, M.D., Suzanna L.R. McDonald, Ph.D., Kyle Bernstein, Ph.D., Alie H. Wurie, M.D., Marion S. Dumbuya, R.N., Neetu Abad, Ph.D., Baimba Idriss, M.D., Teodora Wi, Ph.D., Sarah D. Bennett, M.D., Tina Davies, M.S., Faiqa K. Ebrahim, M.D., Elissa Meites, M.D., Dhamari Naidoo, Ph.D., Samuel Smith, M.D., Anshu Banerjee, Ph.D., Bobbie Rae Erickson, M.P.H., Aaron Brault, Ph.D., Kara N. Durski, M.P.H., Jorn Winter season, Ph.D., Tara Sealy, M.P.H., Stuart T. Nichol, Ph.D., Margaret Lamunu, M.D.D., Oliver Morgan, Ph.D., and Foday Sahr, M.D.1.

Patients in the intervention group also had greater improvement in standard of living, were more satisfied with the care that they received for depression and for diabetes, cardiovascular system disease, or both, and were more likely to have a loss of 1.0 percent or greater in the glycated hemoglobin level from baseline and a decrease of 10 mm Hg or greater in systolic blood pressure . Quality of Care In comparison with controls, patients in the intervention group were a lot more likely to have a number of adjustments in the insulin dose and in antihypertensive and antidepressant medications on the 12-month period.

You Might Also Like